Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021

Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.

[thumbnail of Oncology Fact Sheet Nr.23_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
89kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 700-875 Male genitalia
Language:	English
Series Name:	Oncology Fact Sheet Nr. 23
Deposited on:	29 Oct 2020 12:38
Last Modified:	01 Feb 2021 18:31

Repository Staff Only: item control page